Fig. 3. Fc fusion GDF15 molecules improve metabolic parameters in obese mice and obese cynomolgus monkeys. Fc fusion GDF15 molecules improve metabolic.

Slides:

Advertisements

Similar presentations

The FATZO mouse as a Translational Model for the Development of Drugs for Obesity, Metabolic Syndrome and Diabetes. PreClinOmics, Inc. 1.

Advertisements

TURNING PEPTIDES INTO DRUGS Background Materials & Methods 1) Bataille et al., FEBS Letters, 146, 79-86, ) Gros et al., Endocrinology, 133, ,

The New Dual Glucagon-GLP-1 Agonist ZP2929 Improves Glycemic Control and Reduces Body Weight in Murine Models of Obesity and Type 2 Diabetes Jens R. Daugaard,

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.

Fig. 6. Transgenic expression of αLNNd and mag in dyW/dyW mice improves muscle function, increases body weight, and prolongs life span. Transgenic expression.

Metabolic effects of K107R and rosiglitazone treatment.

Fig. 4. Bexarotene promotes PPARδ activation of target genes in mouse brain and muscle. Bexarotene promotes PPARδ activation of target genes in mouse brain.

Effects of highly concentrated SFN provided as BSE in T2D patients

Volume 23, Issue 3, Pages (March 2016)

Fig. 8. In vivo suppression of MM by CMLD

PVSRIPO-mediated APC activation occurs in immunosuppressive conditions

Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with.

Fig. 1 MT-2 ameliorates asthmatic pulmonary resistance.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 4 Infection-induced CLV dysfunction is associated with decreased LMC coverage. Infection-induced CLV dysfunction is associated with decreased LMC.

Fig. 2. GDF15 crystal structure and enabled design of GDF15 molecules.

Volume 26, Issue 5, Pages e3 (November 2017)

Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 8. Therapeutic effects of the transplantation of hiPSC-EPO–producing cells on renal anemia in adenine-treated mice. Therapeutic effects of the transplantation.

Dot plots of trisomic versus fetal fractions for cohorts 1 and 2

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 1. Serum HBsAg, HBcrAg, and HBeAg reduction in human patients treated with a single dose of ARC-520. Serum HBsAg, HBcrAg, and HBeAg reduction in human.

Fig. 2. Effects of SFN in mouse hepatocytes and in rat models of diet-induced glucose intolerance. Effects of SFN in mouse hepatocytes and in rat models.

Type 1 immunity drives metabolic disease but protects against NAFLD

Fig. 2 STED microscopy of isolated cardiomyocytes from mice treated with MP-rhodamine–loaded CaPs. STED microscopy of isolated cardiomyocytes from mice.

Fig. 6. Safety assessment in cynomolgus monkey.

Fig. 6 pDCs infiltrate the skin of BLM-treated mice, and their depletion attenuates skin fibrosis. pDCs infiltrate the skin of BLM-treated mice, and their.

Volume 22, Issue 6, Pages (February 2018)

Fig. 2. Circulating VEGF in GCA patients up-regulates microvascular endothelial Jagged1. Circulating VEGF in GCA patients up-regulates microvascular endothelial.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 3. ERRα is involved in the regulation of OPLAH.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Fig. 7. Therapeutic effects of hiPSC-EPO protein on renal anemia in adenine-treated mice. Therapeutic effects of hiPSC-EPO protein on renal anemia in adenine-treated.

Fig. 8 SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and in vivo. SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and.

Volume 21, Issue 5, Pages (May 2015)

Comparison of therapeutic efficacies of C12G6 and other bnAbs in mice

Stroke induces atheroprogression via the RAGE-signaling pathway

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 2 In vitro and preclinical study with 18F-MPG.

CD facilitates RCT in vivo and promotes urinary cholesterol excretion

Fig. 4 Surgery initiates a systemic inflammatory response that triggers the outgrowth of distant immunogenic tumors and can be inhibited by perioperative.

Fig. 6 Innate and adaptive immunity, but not ADCC, contributes to M7824 antitumor activity. Innate and adaptive immunity, but not ADCC, contributes to.

Fig. 3 CSF1 is expressed in human melanoma.

Decreased weight and adiposity is transmissible via the gut microbiota

Fig. 1 Schematic of experimental design.

Fig. 4. Local application of FR provides prolonged protection against Gq-dependent airway constriction in normal and OVA-sensitized mice in vivo. Local.

Fig. 5 Treatment with an OX40 agonist antibody of 3-week-old HBVtgRag−/− mice or mice with chronic HBV disease results in an altered immune response to.

Fig. 7. Scale-up of AAV vector–mediated liver gene transfer of secretable GAA to nonhuman primates. Scale-up of AAV vector–mediated liver gene transfer.

Fig. 4. Clearance of 12-mer-1 from a nonhuman primate model.

Fig. 2. CD treatment facilitates regression of murine atherosclerosis.

Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.

Body weight, blood glucose, and iron status in STZ-induced type 1 diabetic rats with or without insulin therapy. Body weight, blood glucose, and iron status.

Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.

Volume 26, Issue 5, Pages e3 (November 2017)

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Glucose tolerance in WT and TRPM2-KO mice.

BAFF-deficient (BAFFnull) and anti-BAFF antibody (Ab)–treated obese mice exhibit superior glucose metabolic control compared with WT and Bnull mice. BAFF-deficient.

Fig. 4 Deletion of hepatocyte HIF-2α does not affect obesity-induced glucose, glucagon, and insulin intolerance. Deletion of hepatocyte HIF-2α does not.

Rapid improvement of glucose tolerance induced by PP

Effects of Rosi treatment on ASKO mice.

Metabolic outcomes associated with DIO in E3FAD and E4FAD mice.

Fig. 2. Effects of SFN in mouse hepatocytes and in rat models of diet-induced glucose intolerance. Effects of SFN in mouse hepatocytes and in rat models.

Fig. 5 Treatment with BMS (PO BID) protects from wasting and colitis in two SCID mouse models. Treatment with BMS (PO BID) protects from.

Fig. 1. The HCN channel blocker ivabradine (IVA) is analgesic in a mouse model of type 1 diabetes. The HCN channel blocker ivabradine (IVA) is analgesic.

Fig. 2. PlGF-2123–144 conjugation reduces systemic exposure to checkpoint blockade Abs and potential treatment-related toxicity. PlGF-2123–144 conjugation.

Fig. 3. Human liver tissue seed graft function.

Fig. 1. GDF15 is up-regulated with obesity, and AAV-GDF15 improves metabolic parameters in DIO mice. GDF15 is up-regulated with obesity, and AAV-GDF15.

Fig. 3. Effects of SFN in mice with diet-induced diabetes.

Presentation transcript:

Fig. 3. Fc fusion GDF15 molecules improve metabolic parameters in obese mice and obese cynomolgus monkeys. Fc fusion GDF15 molecules improve metabolic parameters in obese mice and obese cynomolgus monkeys. (A) Body weight, OGTT glucose AUC, insulin, triglyceride, cholesterol concentrations, and food intake of male C57BL/6 DIO mice treated weekly with vehicle, rosiglitazone, or Fc fusion GDF15 proteins (0.1, 1, or 10 nmol/kg) for 5 weeks (n = 12). *P < 0.05, **P < 0.01, and ***P < 0.001 versus vehicle by ANOVA. (B and C) Cynomolgus monkeys received weekly subcutaneous doses (days 0, 7, 14, 21, 28, and 35) of vehicle (closed square; n = 10), ScFc (open triangle; n = 5), or DhCpmFc (open circle; n = 8) for 6 weeks. (B) Plasma chemistries and body weights were measured 6 days after each weekly injection before the morning meal (days 6, 13, 20, 27, 34, and 41); food intake measurements occurred daily. Data are expressed as group means ± SEM. (C) OGTT data are represented as AUC (glucose AUC, mg/dl per hour; insulin AUC, ng/ml per hour; 0 to 180 min). Cynomolgus monkeys suspected to be positive for anti-GDF15 antibodies were excluded from data analysis (five monkeys for ScFc and two for DhCpmFc). Statistical analysis was performed by analysis of covariance (ANCOVA), and statistical significance is denoted as #P < 0.05, ##P < 0.01, and ###P < 0.01 versus vehicle for ScFc; *P < 0.05, **P < 0.01, and ***P < 0.01 versus vehicle for DhCpmFc. Yumei Xiong et al., Sci Transl Med 2017;9:eaan8732 Published by AAAS